middle.news
Nyrada Advances Xolatryp Phase IIa Trial with AU$6.74M Cash and Expanded Oncology Research
8:58am on Wednesday 15th of April, 2026 AEST
•
Biotechnology
Read Story
Nyrada Advances Xolatryp Phase IIa Trial with AU$6.74M Cash and Expanded Oncology Research
8:58am on Wednesday 15th of April, 2026 AEST
Key Points
Ethics approval received for Xolatryp Phase IIa trial in myocardial infarction
Patient recruitment to start April 2026 at confirmed hospital sites
AU$6.74 million cash on hand with AU$2.45 million R&D tax rebate expected
Preclinical studies initiated for oncology and cardioprotection against chemotherapy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE